$0.99
+0.00 (+0.17%)
Open$0.99
Previous Close$0.98
Day High$1.02
Day Low$0.96
52W High$3.31
52W Low$0.76
Volume—
Avg Volume798.0K
Market Cap79.27M
P/E Ratio—
EPS$-0.67
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+996.7% upside
Current
$0.99
$0.99
Target
$10.81
$10.81
$7.63
$10.81 avg
$13.89
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 715.8K | 622.5K | 16.05M |
| Net Income | -55,170,462 | -43,180,638 | -3,462,613 |
| Profit Margin | -7,732.0% | -7,345.4% | -21.6% |
| EBITDA | -58,467,822 | -48,303,705 | -3,307,317 |
| Free Cash Flow | — | — | -2,137,974 |
| Rev Growth | +15.0% | +15.0% | +0.8% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |